ANTIBODY THERAPEUTICS XCHANGE
EUROPE 2023
Zurich, December 6
Welcome to hubXchange’s Europe Antibody Therapeutics Xchange 2023, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing antibody therapeutics, through a series of roundtable discussions.
Discussion topics will cover Target Selection, Lead Identification & Optimization, Formats & Scaffolds, Bi/Multi-Specifics and Emerging Technologies.
Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.
Please note this is an In-Person meeting.
VENUE DETAILS: Hilton Zurich Airport Hotel, Hohenbuehlstrasse 10 – 8152 Opfikon, Switzerland
SNAPSHOTS OF DISCUSSION TOPICS
- Computational approach for target selection
- How to ensure target specificity to avoid unintended interactions with other proteins and molecule
- Challenging membrane antibody targets: Brainstorming in-parallel in vivo and in vitro methodologies to identify rare and precious functional Ab candidates
- One size doesn’t fit all: Key considerations for successful therapeutic antibody discovery for various modalities and indications
- Fc engineering for improved antibody druggability
- Considerations for CAR-T/ CAR-NK cell binder format designs during screening and selections
- Developing bispecifics targeting novel targets
- Immuno-oncology tumour-specific approach through multispecific therapeutics
- Novel delivery modes for biologics – beyond parenteral administration and beyond classical protein administration
- Using AI, AlphaFold and ML methods for therapeutics discovery and optimization
Full Xchange Agenda
Click on each track for detailed agenda
Target Selection
Lead Identification & Optimization
Formats & Scaffolds
Bi/Multi-Specifics
Emerging Technologies
Target Selection
Time
Titles and Bullets
Facilitator
8:00 – 8:30
Registration
8:30 – 9:00
Opening Address & Keynote Presentation by Nona Biosciences
Building Next-Gen Biologics Leveraging Industry-Leading Fully Human Heavy Chain Only Antibody Platforms
HCAb Harbour Mice of Nona Biosciences is the first fully human heavy chain only antibody (HCAb) transgenic mice platform in history. It is optimized, clinically validated with global patent protection. HCAb Harbour Mice efficiently produces high affinity, and functional HCAbs with excellent biophysical characteristics. Fully human heavy chain only antibodies are the ideal antibody format to generate a multitude of next-generation therapeutic modalities including bispecific/multispecific antibodies, CART, ADC, and mRNA therapy.
Dr. Jiyong Zhang is the Head of Business Development of Nona Biosciences. Nona Biosciences is a global biotech technology focusing on innovation of antibody therapy. Jiyong has 10+ years’ experience on therapeutic antibody research and bispecific antibody engineering. Jiyong received his PhD in Pharmacology from Okayama University, Japan, and completed his postdoc training at Brown University, US. Prior joining Nona, Jiyong has worked at Alexion and Abbvie focusing on antibody discovery, engineering, and bispecific antibody R&D.
9:05 – 10:05
Computational approach for target selection
- Inability to demonstrate efficacy remains the biggest reason for clinical failure, this can be traced right back to the initial selection of a drug target(s).
- Selecting the ‘right’ target in the ‘right’ patient population is key to successfully. improving patient lives.
- Advances in genetic analysis, multi-omic studies, pathway analysis, and organoid human disease models have all helped.
- However, identifying unique causal drug targets from these great quantities of data and literature remain a constant challenge.
Laura heads the Target Validation and Tractability team for UK research at UCB. Her position involves combining analysis of academic activity, research into biological pathways, disease areas and therapeutic modalities (including NBE/NCE and gene therapy). She has been a scientist, therapeutic project (both conventional and bi-specific modalities), and people leader at UCB for sixteen years. Previously heading up the Antibody Selection team for bi-specific target discovery, where they delivered thousands of bi-specific antibody pairings for therapeutic target discovery in immunology and tissue remodeling. She’s keen to learn more about the use of novel therapeutic modalities, and new ways to identify targets.
10:10 – 10:40
1-2-1 Meetings/Networking Break
10:40 – 11:10
1-2-1 Meetings/Networking Break
11:10 – 11:20
Morning refreshments
12:20 – 13:20
Networking Lunch
13:50– 14:20
1-2-1 Meetings/Networking Break
14:20 – 14:50
1-2-1 Meetings/Networking Break
15:30 – 16:00
1-2-1 Meetings/Networking Break
16:05 – 17:05
How to select novel and differentiated antibody targets with causal disease links
- Inability to demonstrate efficacy remains the biggest reason for clinical failure, this can be traced right back to the initial selection of a drug target(s).
- Selecting the ‘right’ target in the ‘right’ patient population is key to successfully improving patient lives.
- Advances in genetic analysis, multi-omic studies, pathway analysis, and organoid human disease models have all helped.
- However, identifying unique causal drug targets from these great quantities of data and literature remain a constant challenge.
Laura heads the Target Validation and Tractability team for UK research at UCB. Her position involves combining analysis of academic activity, research into biological pathways, disease areas and therapeutic modalities (including NBE/NCE and gene therapy). Laura has been a scientist, therapeutic project (both conventional and bi-specific modalities), and people leader at UCB for sixteen years. Previously heading up the Antibody Selection team for bi-specific target discovery, where we delivered thousands of bi-specific antibody pairings for therapeutic target discovery in immunology and tissue remodelling. She is keen to learn more about the use of novel therapeutic modalities, and new ways to identify targets.
17:05– 18:05
Drinks-Canape Reception
Partners
Previous
Next
Antibody Therapeutics Xchange | Europe 2023
Register